Department of Health and Human Services, October 2008, is my understanding correct that despite the fact that IFN, antivirals, and their combinations thereof all may improve liver surrogates such as HBV DNA, HBeAg loss, HBeAg seroconversion, ALT normalization, histological improvement, combined virologic
and biochemical outcomes, fundamentally, they do not reduce the chances for
mortality, cirrhosis, hepatic decompensation, and hepatocellular carcinoma because they do not improve HBsAg clearanc